This transcript provides a detailed pathology discussion of Low-Grade Fibromyxoid Sarcoma (LGFMS), also known as Evans' Tumor, referencing a case of a 6 cm intramuscular thigh mass in a 45-year-old woman. LGFMS is characterized as an unusual malignancy that appears histologically benign (bland, low cellularity, minimal pleomorphism or mitoses) but behaves aggressively, often exhibiting recurrence or metastasis many years after initial diagnosis (with a mean time to metastasis of about 15 years). Microscopically, the tumor shows a characteristic alternation between fibrous (pink) and myxoid (bluish) areas, containing delicate, thread-like collagen. LGFMS is confirmed to be a fusion-driven sarcoma (FUS-CREB3L2/3L1) and can be reliably diagnosed using MUC4 immunohistochemistry. The speaker emphasizes the critical diagnostic pitfall of mistaking this lesion for a benign entity like neurofibroma or a generic fibroma, stressing that all benign-appearing, unnamed neoplasms require expert consultation due to potential underlying malignancy.
0:11 Case Introduction: The discussion is based on a case involving a 45-year-old woman presenting with a 6 cm intramuscular thigh mass.
0:28 Tumor Identity and History: The tumor is identified as Low-Grade Fibromyxoid Sarcoma (LGFMS), also known as Evans' Tumor, named after Dr. Harry Evans who first described it in the 1980s after observing initial misdiagnoses (e.g., desmoid fibromatosis, neurofibroma) that later metastasized.
1:27 Nomenclature and Histological Comparison: LGFMS differs from Myxofibrosarcoma (MFS). MFS is typically more myxoid/blue (Myxo comes first), while LGFMS is often more fibrous/pink (Fibro comes first), although exceptions exist.
1:57 The Malignancy Paradox: LGFMS is highly unusual because it generally does not look malignant (low cellularity, bland uniform cells, few mitoses, lack of necrosis or pleomorphism) but behaves as a malignant sarcoma.
2:21 Extremely Late Recurrence/Metastasis: A key distinguishing feature is the tendency for recurrence or metastasis many years post-diagnosis. The mean time to metastasis or recurrence is approximately 15 years, with some cases showing events three or four decades later.
3:25 Low Power Diagnostic Features: The two main low-power keys are:
Alternating zones of fibrous (pink, collagenous) and mixoid (bluish) areas.
Alternating cellularity, ranging from low to medium cellularity and sometimes near-acellular areas.
4:23 Microscopic Details: The cells may exhibit a slight waviness, potentially leading to confusion with neural tumors (like neurofibroma). The fibrous areas often show the "ramen noodle sign" (very wavy dense collagen), suggesting a fibroblastic process rather than a neural one.
5:29 Diagnostic Pitfalls: LGFMS can be mistaken for Neurofibroma or Desmoid Fibromatosis. Pathologists should avoid using the term "fibroma not otherwise specified," as this often leads to missing pattern-based malignancies.
Pathology Pearl (6:30): If a neoplasm looks benign but lacks a specific name, consult an expert, as some tumors (like LGFMS and Myxoid Liposarcoma) are malignant based purely on pattern, not necessarily high-grade features.
7:56 Characteristic Collagen: LGFMS features delicate, thread-like collagen fibers with pale, mixoid ground substance diffused between them.
9:02 Molecular Basis and Diagnosis: LGFMS is a fusion sarcoma, specifically driven by the FUS-CREB3L2 or FUS-CREB3L1 fusion. It can be diagnosed using:
Molecular testing for the fusion.
Immunohistochemistry (IHC) for MUC4 (a sensitive and relatively specific marker).
9:49 Fusion Sarcoma Pearl: Sarcomas driven by specific gene fusions (like LGFMS, Synovial Sarcoma, Ewing Sarcoma) tend to have monotonous, uniform nuclei because every cell shares the same genetic abnormality, unlike high-grade tumors which often show pleomorphism resulting from random chromosomal changes.
10:51 Prognosis Note: While LGFMS is usually found in deep soft tissue, smaller, superficial lesions, especially in children, may have a better prognosis, though long-term follow-up is needed due to the tumor's lengthy disease course.